Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)

NCT ID: NCT04597437

Last Updated: 2025-07-28

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 74 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-03-15
• Study Completion Date: 2026-09-30

Brief Summary

ZAP-DENGUE is a pilot randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of five days of intravenous zanamivir treatment to treat vascular permeability syndrome which is the main cause of death in dengue fever.

Detailed Description

ZAP-DENGUE is a pilot randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of five days of intravenous zanamivir treatment to treat vascular permeability syndrome which is the main cause of death in dengue fever. Our central hypothesis is that zanamivir treatment is safe in patients with dengue infection, will significantly decrease serum sialic acid levels, and will result in fewer patients with the development of moderate or severe clinical plasma leakage. 74 male and non-pregnant female volunteers age 7 years and older from Colombia with a diagnosis of dengue fever with warning signs or severe dengue as per the World Health Organization 2009 definition with the presence of fever and positive rapid test for the presence of dengue non-structural protein-1 (NS1) will be randomized to zanamivir versus placebo. In the treatment group, all participants weighing less than 50 kg will receive 12 mg/kg and all participants weighing 50 kg and above will receive 600 mg as the initial dose intravenously every twelve hours for 5 days adjusted for renal function. In the placebo group, participants will receive placebo normal saline solution intravenously every twelve hours for 5 days.

All patients will receive blood draws for assessment of hematocrit, renal function, and biologic efficacy endpoints and clinical evaluation of signs and symptoms of vascular permeability (which may include ultrasound and radiograph) and adverse events daily during the five days of medication administration and once at follow up at 14 days.

Conditions

Dengue Fever

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Zanamivir

In the treatment group, participants weighing less than 50 kg will receive 12 mg/kg and those weighing 50 kg and above will receive 600 mg as the initial dose intravenously every twelve hours for 5 days adjusted for renal function.

Group Type: EXPERIMENTAL

Zanamivir

Intervention Type: DRUG

Intravenous zanamivir

Placebo

In the placebo group, participants will receive placebo normal saline solution intravenously every twelve hours for 5 days.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

In the placebo group, participants will receive placebo normal saline solution intravenously every twelve hours for 5 days.

Interventions

Zanamivir

Intravenous zanamivir

Intervention Type: DRUG

Placebo

In the placebo group, participants will receive placebo normal saline solution intravenously every twelve hours for 5 days.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Provision of signed and dated informed consent form.

2. Stated willingness to comply with all study procedures and availability for the duration of the study.

3. Male or female, aged >7 years

4. Willingness to receive intravenous medication and be willing to adhere to the medication regimen

5. Have a diagnosis of dengue by dengue NS1 rapid test

6. Have had a self-informed fever >38 degrees C in the last 3 days.

7. Have dengue with warning signs as per the 2009 WHO criteria including one of the following: abdominal pain or tenderness, persistent vomiting, clinical fluid accumulation, mucosal bleeding, lethargy, restlessness, liver enlargement over 2 cm, augmented hematocrit, thrombocytopenia or severe dengue defined as dengue with severe plasma leakage leading to dengue shock and/or fluid accumulation with respiratory distress; severe hemorrhage; severe organ impairment (hepatic damage, renal impairment, cardiomyopathy, encephalopathy or encephalitis).

8. Enrollment in EPS (Entidadas Promotoras de Salud) or Sistema General de Seguridad Social en Salud (SGSSS)- Colombian Public Health Insurance.

Exclusion Criteria

1. Pregnancy or lactation

2. Children in Care of the state

3. Patients who are unlikely to survive 48 hours

4. Unstable cardiac disease or arrhythmia at baseline

5. History of significant cardiac disease

6. Treatment with another investigational drug or other intervention within 1 month.

7. Encephalitis or unable to consent

• Minimum Eligible Age: 7 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Naval Medical Research Center

FED

Sponsor Role: collaborator

Clinica de la Costa

UNKNOWN

Sponsor Role: collaborator

Global Disease Research

UNKNOWN

Sponsor Role: collaborator

Universidad Libre de Barranquilla

UNKNOWN

Sponsor Role: collaborator

George Washington University

OTHER

Sponsor Role: lead

Responsible Party

Aileen Y Chang

PI

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Aileen Chang, MD

Role: PRINCIPAL_INVESTIGATOR

George Washington University

Locations

Cien Salud IPS SAS

Barranquilla, Atlántico, Colombia

Site Status: ACTIVE_NOT_RECRUITING

Clinica de la Costa SAS

Barranquilla, Colombia, Colombia

Site Status: RECRUITING

Countries

Colombia

Central Contacts

Aileen Y Chang, MD

Role: CONTACT

chang@email.gwu.edu

202-741-6562

Alfonso Sucerquia, MD

Role: CONTACT

alfonso.sucerquiahernandez@email.gwu.edu

202-741-6562

Facility Contacts

Andres Cadena, MD

Role: primary

acadena@clinicadelacosta.co

Camilo Fernandez

Role: backup

cfernandez@clinicadelacosta.co

Other Identifiers

NCR203024

Identifier Type: -

Identifier Source: org_study_id